HZNP - Horizon Therapeutics ticks lower on report of FTC 2nd request in Amgen deal

• Horizon Therapeutics ( NASDAQ: HZNP ) ticked down 0.3% on a report that Amgen ( NASDAQ: AMGN ) received a so-called "2nd request" from the Federal Trade Commission in regards to its planned almost $28 billion acquisition.
• Horizon ( HZNP ) and Amgen ( AMGN ) are said to have received the request for a more in-depth probe from the FTC as a deadline for the regulatory agency expired, according to a CTFN report.
• Amgen ( AMGN ) agreed to acquire rare-disease-focused Horizon Therapeutics for $116.50 per share in cash last month, valuing the Ireland-based biotech at nearly $27.8 billion.
• The FTC request comes as Sen. Elizabeth Warren (D-MA) on Wednesday wrote a letter to the the antitrust regulator about her concerns with the transaction.

For further details see: